Articles related to COMBINATION THERAPY

In managing acute decompensated heart failure, optimizing loop diuretic therapy is pivotal; initial aggressive dosing tailored to urinary outputs can significantly improve patient outcomes.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.

The TASTE-SL trial presents compelling evidence that Sanbexin, a sublingual combination of edaravone and dexborneol, offers a significant improvement in recovery for acute ischemic stroke patients, marking a notable advancement in neuroprotective treatment strategies.